RecruitingPhase 1Phase 2NCT06697197

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

A Phase 1/2 Study of BMS-986482 as Monotherapy or Combination Therapy in Participants With Advanced Solid Tumors

Sponsor

Bristol-Myers Squibb

Enrollment

413 participants

Start Date

Feb 17, 2025

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumors

Summary

The purpose of this study is to test the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called BMS-986482, a drug called Bevacizumab, and others for people with advanced solid tumors. The study is currently recruiting participants at 21 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBMS-986482

Specified dose on specified days

DRUGNivolumab and rHuPH20

Specified dose on specified days

DRUGNivolumab/relatlimab/rHuPH20

Specified dose on specified days

DRUGBevacizumab

Specified dose on specified days

Locations(21)

University of California, Irvine (UCI) Health - UC Irvine Medical Center

Irvine, California, United States

The Angeles Clinic and Research Institute - West Los Angeles Office

Los Angeles, California, United States

Local Institution - 0008

Aurora, Colorado, United States

John Theurer Cancer Center at Hackensack University Medical Center

Hackensack, New Jersey, United States

Northwell Health/ RJ Zuckerberg Cancer Center

Lake Success, New York, United States

Levine Cancer Institute

Charlotte, North Carolina, United States

Fred Hutchinson Cancer Center

Seattle, Washington, United States

UZ Gent

Ghent, Oost-Vlaanderen, Belgium

Rigshospitalet

Copenhagen, Capital Region, Denmark

Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone

Marseille, Bouches-du-Rhône, France

Gustave Roussy

Villejuif, Paris, France

General Hospital of Athens "Laiko"

Athens, Attikí, Greece

Papageorgiou General Hospital of Thessaloniki

Thessaloniki, Thessaloníki, Greece

Fondazione IRCCS Istituto Nazionale dei Tumori

Milan, Lombardy, Italy

Istituto Clinico Humanitas

Rozzano, Milano, Italy

Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL)

Amsterdam, North Holland, Netherlands

Erasmus Medisch Centrum

Rotterdam, Netherlands

Hospital Universitari Vall d'Hebron

Barcelona, Barcelona [Barcelona], Spain

Clinica Universidad de Navarra

Pamplona, Navarre, Spain

Hospital Universitario HM Sanchinarro

Madrid, Spain

Karolinska Universitetssjukhuset Solna

Solna, Stockholms Län [se-01], Sweden

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06697197

Related Trials

Study of GS-2426 in Participants With Advanced Solid Tumors

NCT076012432 locations

A Study of BG-C477 in Participants With Advanced Solid Tumors

NCT0659647354 locations

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

NCT073973386 locations

A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

NCT0506728375 locations

A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors

NCT0679255217 locations